Lyme disease-associated T cell receptor-related methods
Provided are methods for assessing T cell receptor β chain complementary determining region 3 (TCRβ CDR3) sequences. In certain embodiments, the methods comprise assessing TCRβ CDR3 sequences determined from a sample obtained from a subject having or suspected of having a tick bite for the presence or absence of one or more TCRβ CDR3 sequences set forth in the present disclosure. According to some embodiments, at the time of the assessing, the subject is seronegative for Lyme disease and/or has one or more non-specific symptoms consistent with Lyme disease. Also provided are methods comprising administering a Lyme disease therapy to a subject identified as comprising T cells that express a T cell receptor β chain (TCRβ) comprising a TCRβ CDR3 sequence set forth in the present disclosure.
1. A computer-implemented method for assessing T cell receptor β chain complementary determining region 3 (TCRβ CDR3) sequences, the method comprising:
assessing TCRβ CDR3 sequences determined from a sample comprising T cells obtained from a subject for the presence or absence of one or more TCRβ CDR3 sequences set forth in SEQ ID NOs: 200, 280, 347, 618, 779, 1026, 1046, 1084, 1688, and 1809;
identifying the subject as having Lyme disease based on the assessment when the one or more TCRβ CDR3 sequences are present; and
administering a therapeutically effective amount of a Lyme disease therapy to the subject, wherein the Lyme disease therapy comprises an oral antibiotic therapy, an intravenous antibiotic therapy, or a combination thereof.
2. The computer-implemented method of claim 1 , wherein the subject has or is suspected of having a tick bite that occurred within two weeks prior to the assessing.
3. The computer-implemented method of claim 1 , wherein the subject is seronegative for Lyme disease at the time of the assessing.
4. The computer-implemented method of claim 1 , wherein the subject has one or more non-specific symptoms consistent with Lyme disease at the time of the assessing, wherein the one or more non-specific symptoms are selected from the group consisting of: skin erythema, fatigue, arthralgia, and any combination thereof.
5. The computer-implemented method of claim 1 , comprising assessing the TCRβ CDR3 sequences for the presence or absence of three or more TCRβ CDR3 sequences set forth in SEQ ID NOs: 200, 280, 347, 618, 779, 1026, 1046, 1084, 1688, and 1809.
6. The computer-implemented method of claim 1 , comprising assessing the TCR(CDR3 sequences for the presence or absence of each of the TCRβ CDR3 sequences set forth in SEQ ID NOs: 200, 280, 347, 618, 779, 1026, 1046, 1084, 1688, and 1809.
7. The computer-implemented method of claim 1 , wherein the Lyme disease therapy comprises an oral antibiotic therapy.
8. The computer-implemented method of claim 7 , wherein the oral antibiotic therapy comprises oral administration of a therapeutically effective amount of an antibiotic selected from the group consisting of: doxycycline, amoxicillin, cefuroxime axetil, and any combination thereof.
9. The computer-implemented method of claim 1 , wherein the Lyme disease therapy comprises an intravenous antibiotic therapy antibiotic therapy.
10. The computer-implemented method of claim 9 , wherein the intravenous antibiotic therapy comprises intravenous administration of a therapeutically effective amount of an antibiotic selected from the group consisting of: ceftriaxone, cefotaxime, penicillin G, and any combination thereof.